We will develop and commercialize high-value, multi-marker, diagnostic tests which address unmet needs in gynecologic oncology and women’s health. We will accomplish our mission through internal development, targeted acquisitions, and collaborations with leading scientific and clinical institutions. Our global commercial efforts will include direct marketing and sales activities as well as partnerships with leading companies in women’s health.

Research Grants 6 show all


$116K
2004

$15.1M
2005

$37.3K
2006

$42.3K
2008

$34.3K
2009

Patents 598show all

  • 309
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 132
    H01J - Electric discharge tubes or discharge lamps
  • 97
    B01J - Chemical or physical processes, e.g. catalysis or colloid chemistry
  • 77
    B01D - Separation
  • 69
    C40B - Combinatorial chemistry
  • 64
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 50
    C07K - Peptides
  • 47
    Y02A - Technologies for adaptation to climate change
  • 32
    G16B - Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology
  • 24
    B01L - Chemical or physical laboratory apparatus for general use

Clinical Trials 2show all

1N/A

SEC Filings show all


241
8-K

58
10-Q

17
10-K

3
D

1
S-1

Contact Information

12117 Bee Caves Road Building Three, Suite 100
Austin, TX 78738
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$89,992,35811-502017-02-14Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-12-23$10,500,000Post Ipo EquityOracle Investment Management Inc., Birchview Fund, Jack Schuler
2013-05-24$13,242,500Post Ipo EquityOracle Investment Management Inc.
2017-02-14$5,600,000Post Ipo Equity
2013-12-20$17,600,000Post Ipo EquityOracle Investment Management Inc., Matthew W. Strobeck, Jack Schuler
2010-01-12$43,049,858Post Ipo Equity

SEC Form D Funding Events

DateOfferedSoldType
2013-05-24$13,242,500$13,242,500Equity, Option to Acquire
2010-01-12$43,049,858$43,049,858Equity
2007-09-17Unknown Unknown Other (Paper Filing)

Key Executives

  • Gail S. Page
    Director
  • John F. Hamilton
    Director
  • James S. Burns
    Director
  • Thomas McLain
    Executive Officer
  • Eric Schoen
    Executive Officer
  • Donald Munroe
    Executive Officer
  • William Creech
    Executive Officer
  • Bruce Huebner
    Director
  • James Burns
    Director
  • Peter Roddy
    Director
  • Carl Severinghaus
    Director
  • William Wallen
    Director
  • Robert Goggin
    Director